Charles river and purespring therapeutics announce gene therapy manufacturing collaboration

Wilmington, mass.--(business wire)--charles river laboratories international, inc. (nyse: crl) and purespring therapeutics, a pioneering gene therapy company focused on transforming the treatment of kidney diseases, today announced a plasmid dna contract development and manufacturing organization (cdmo) collaboration.
CRL Ratings Summary
CRL Quant Ranking